Stage 4 Prostate Cancer Prognosis

Stage 4 Prostate Cancer Prognosis
Stage 4 prostate cancer prognosis - If prostate cancer has spread to nearby lymph nodes or in remote parts of the body, it is called metastatic prostate cancer. Hormone therapy will generally improve the symptoms and will delay cancer development for 2 to 3 years. If only lymph nodes are involved, a man can use hormone therapy to delay the progression of prostate cancer much more; However, most of those who had positive lymph nodes at the time of hormonal therapy would still be in danger of developing an additional metastatic disease within 10 years of treatment.

Bone metastases tend to be less responsive to hormone therapy. Stage 4 prostate cancer prognosis. People who are experiencing prostate cancer naturally worry about their future. Understanding prostate cancer and what is expected can help patients and loved ones to plan adequate care, think about lifestyle changes and make decisions about the quality of life and finance. Many people with prostate cancer want to know their prognosis so that they could ask their doctors or seek prostate cancer statistics by themselves.

While some people find it easier to cope with statistics, others find confusing and frightening statistical information and consider it too impersonal to use them. The Doctor who is most familiar with the situation of the patient is in the best position to discuss the prognosis of prostate cancer and to explain what statistics about prostate cancer that may occur in that person. At the same time, it is important to understand that even doctors do not know exactly what will happen. In fact, a person's prognosis can change if cancer develops or if the treatment is successful. The search for forecast information is a personal decision and every patient must decide how much information he wants to know and how to overcome it.

Stage 4 prostate cancer prognosis. Chances are alive, without disease, before diagnosis 10 years or 15 prostate cancer is often more dependent on your stage and cancer level, rather than on prostate cancer treatment. As expected, the best prognosis for prostate cancer is suitable for patients with small tumors, slow growth, and good differentiation. The good news is that about three-fourths of all newly diagnosed clinical prostate cancers are localized (phase I or Phase II). About 15% is the third stage, and 11% is the fourth phase. In the diagnosis, the average age of 72 years, many prostate cancer men in the next 10-15 years died of other natural causes. Some men with the low local disease die from prostate cancer. Specific disease survival-excluding other causes of death are close to 90%. In other words, whether treatment-waiting, surgery or radiotherapy-such people can treat his cancer as a chronic disease because he is more likely to die than other causes of prostate cancer.

Patients who choose to wait for vigilance may be more likely to develop the metastatic disease if their lifespan is long enough. In a group of studies, the chances of metastasis in 10 years were 19% for the well-differentiated males and 42% for men with different tumors.

Stage 4 prostate cancer prognosis. Only one small study directly compared waiting and radical prostatectomy, and found no significant difference in survival rates. Surgery or radiotherapy is usually chosen by tumor patients, although it appears to be localized, wider or less differentiated (Grissom score 8-10). Without active treatment, about three-fourths of men will develop the metastatic disease over the next 10 years, and Two-thirds will die of prostate cancer. What treatment is being studied can change that outcome.